The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

2019208 citationsJournal Articlebronze Open Access

Authors

Laura Moreno · Navarre Institute of Health Research

Cristina Pérez · Navarre Institute of Health Research

Aintzane Zabaleta · Navarre Institute of Health Research

Irene Manrique · Navarre Institute of Health Research

Diego Alignani · Navarre Institute of Health Research

Daniel Ajona · Navarre Institute of Health Research

Laura Blanco

Abstract

This study provides a framework to understand response determinants in patients treated with isatuximab based on the number of MoA triggered by CD38 levels of expression, and for the design of effective combinations aimed at capitalizing disrupted tumor-stroma cell protection, augmenting NK lymphocyte-mediated ADCC, or facilitating ADCP in CD38<sup>lo</sup> MM patients.<i>See related commentary by Malavasi and Faini, p. 2946</i>.

Topics & Keywords

Multiple Myeloma Research and Treatments Peptidase Inhibition and Analysis T-cell and B-cell Immunology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 10, pp. 3176-3187

DOI: 10.1158/1078-0432.ccr-18-1597

Field-Weighted Citation Impact: 22.93